Frontline Nilotinib in Pediatric Chronic Myeloid Leukemia: An Interim Analysis of SCCCG[PLUS]-CML 2023
Background: Evidence on the depth of molecular response and long-term tolerability of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase (CML-CP) remains limited. Methods: Children with newly diagnosed BCR::ABL1-positive CML-CP received nilotinib 230 mg/m2 twice daily in a prospective multicenter cohort. BCR::ABL1 on the International Scale (IS) was assessed at scheduled visits; major molecular response (MMR), MR4, and MR4.5 were summarized among patients with data at cycles 3, 6, and 12. Adverse events were graded using Common Terminology Criteria for Adverse Events version 5.0. Nilotinib trough concentrations were assessed in 54 patients using morning predose blood samples analyzed at a specialized third-party clinical laboratory. Results: Ninety-two children were included (median age, 10.3 years [IQR, 7.6–12.5]); 64 (69.6%) were male. MMR was recorded in 22/78 (28.2%), 37/64 (57.8%), and 40/50 (80.0%) evaluable patients at cycles 3, 6, and 12, respectively. At cycle 12, 19/50 (38.0%) had MR4 and 15/50 (30.0%) had MR4.5. At a median follow-up of 1.79 years (IQR, 1.09–2.83), the estimated 2-year event-free survival was 96.4% (95% CI, 86.1–99.1%). Common adverse events included ALT elevation (60/90, 66.7%), myelosuppression (43/87, 49.4%), hyperbilirubinemia (35/89, 39.3%), and rash (29/92, 31.5%). At cycle 6, nilotinib trough concentration showed a modest inverse correlation with BCR::ABL1 transcript levels (Spearman ρ = −0.329, p = 0.044). Conclusions: Frontline nilotinib produced clinically meaningful molecular responses in evaluable pediatric patients with CML-CP. The observed association between trough concentration and molecular response was modest and exploratory and requires prospective validation.
Authors
- Qiao-Ru Li
- X. Zhang (ORCID: https://orcid.org/0009-0001-6819-023X)
- Li‐Bin Huang (ORCID: https://orcid.org/0000-0002-2614-5764)
- W Wan
- Xin Tian (ORCID: https://orcid.org/0000-0001-9601-3751)
- Liuhua Liao (ORCID: https://orcid.org/0000-0002-2869-3705)
- 林丽敏
- 何飞
- Min-Hui Zeng
- Huirong Mai (ORCID: https://orcid.org/0000-0002-8970-9221)
- Xue-Qun Luo
- Haixia Guo (ORCID: https://orcid.org/0009-0001-0994-9357)
- Xiaoyan Yang (ORCID: https://orcid.org/0000-0003-3293-6201)
- Hongying Wei (ORCID: https://orcid.org/0000-0002-5557-4189)
- Fan Zhong (ORCID: https://orcid.org/0000-0003-2632-011X)
- Xing‐Jiang Long (ORCID: https://orcid.org/0009-0004-6530-5486)
- Cong Liang (ORCID: https://orcid.org/0000-0002-5572-5354)
- Xiaobo Zhou (ORCID: https://orcid.org/0000-0002-1003-8745)
- Biyun Guo (ORCID: https://orcid.org/0000-0002-5032-9213)
- Dun-hua Zhou
- Hao-Yan Ren
- Ya-Wei Zou
- Qi-Wen Chen
- Hui-Qin Chen
- Wei-Na Zhang
- Xiu-Ya Huang
- He-Kui Lan
- Wen-Jie Xiong
- Li-Li Liu
- Qiang Fu
- Li-Hua Yang
Institutions
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Hunan Normal University (CN)
- Guangdong Medical College (CN)
- Shantou University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Liuzhou General Hospital (CN)
- Kunming Children's Hospital (CN)
- Sun Yat-sen Memorial Hospital (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Nanfang Hospital (CN)
- Guangzhou Women and Children Medical Center (CN)
- Zhongshan People's Hospital (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Zhujiang Hospital (CN)
- Second Affiliated Hospital of Shantou University Medical College (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- The Second Nanning People's Hospital (CN)
- Huizhou Central People's Hospital (CN)
- Wuhan Children's Hospital (CN)
- Jiangxi Provincial Children's Hospital (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Hunan Provincial People's Hospital (CN)
- Shenzhen Children's Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Huazhong University of Science and Technology (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Biomedicines
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3390/biomedicines14112645
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Basic and Applied Basic Research Foundation of Guangdong Province